Recently Added Drugs

1. Akeega patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12383543 JANSSEN BIOTECH NA
Jul, 2037

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET

More Information on Dosage

AKEEGA family patents

Family Patents

2. Anoro Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12396986 GLAXOSMITHKLINE NA
Nov, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Arynta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12433859 AZURITY NA
Apr, 2040

(14 years from now)




Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Market Authorisation Date: 16 June, 2025

Treatment: Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd)

Dosage: SOLUTION

More Information on Dosage

ARYNTA family patents

Family Patents

4. Aurlumyn patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12409184 BTG INTL NA
Aug, 2041

(15 years from now)

US12409183 BTG INTL NA
Jul, 2044

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 13, 2027
Orphan Drug Exclusivity(ODE-465) Feb 13, 2031

Drugs and Companies using ILOPROST ingredient

Market Authorisation Date: 13 February, 2024

Treatment: Treatment of severe frostbite in adults to reduce the risk of digit amputations

Dosage: SOLUTION

More Information on Dosage

AURLUMYN family patents

Family Patents

5. Caplyta patent expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12409176 INTRA-CELLULAR NA
Mar, 2039

(13 years from now)

US12410195 INTRA-CELLULAR NA
Dec, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-882) Dec 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of depressive episodes associated with bipolar disorder

Dosage: CAPSULE

More Information on Dosage

CAPLYTA family patents

Family Patents

6. Crexont patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403099 IMPAX NA
Oct, 2034

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 07, 2027

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 07 August, 2024

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

CREXONT family patents

Family Patents

7. Cuvrior patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12358861 ORPHALAN NA
May, 2039

(13 years from now)

US12358862 ORPHALAN NA
May, 2039

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 28, 2025
Orphan Drug Exclusivity(ODE-401) Apr 28, 2029

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson's disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET

How can I launch a generic of CUVRIOR before it's drug patent expiration?
More Information on Dosage

CUVRIOR family patents

Family Patents

8. Danziten patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403140 AZURITY NA
Feb, 2040

(14 years from now)




Drugs and Companies using NILOTINIB TARTRATE ingredient

Market Authorisation Date: 07 November, 2024

Treatment: NA

Dosage: TABLET

More Information on Dosage

DANZITEN family patents

Family Patents

9. Dawnzera (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127276 IONIS PHARMS INC Conjugated antisense compounds and their use
May, 2034

(8 years from now)

US9181549 IONIS PHARMS INC Conjugated antisense compounds and their use
May, 2034

(8 years from now)

US9670492 IONIS PHARMS INC NA
Aug, 2034

(8 years from now)

US10294477 IONIS PHARMS INC NA
May, 2035

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9315811 IONIS PHARMS INC NA
Oct, 2032

(7 years from now)




Drugs and Companies using DONIDALORSEN SODIUM ingredient

Market Authorisation Date: 21 August, 2025

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older

Dosage: SOLUTION

More Information on Dosage

DAWNZERA (AUTOINJECTOR) family patents

Family Patents

10. Eligard Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12397120 TOLMAR NA
Dec, 2041

(16 years from now)




Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 23 January, 2002

Treatment: Treatment of advanced prostatic cancer

Dosage: POWDER

More Information on Dosage

ELIGARD KIT family patents

Family Patents

11. Enbumyst patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123319 CORSTASIS THERAP NA
Dec, 2040

(15 years from now)




Drugs and Companies using BUMETANIDE ingredient

Market Authorisation Date: 12 September, 2025

Treatment: NA

Dosage: SPRAY

More Information on Dosage

ENBUMYST family patents

Family Patents

12. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12409186 ASTRAZENECA AB NA
Apr, 2041

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Reducing the risk of sustained egfr decline, end-stage kidney disease, cv death, and hospitalization for heart failure in adults with ckd at risk of progression and without type ii diabetes after at l...

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

13. Fensolvi Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12397120 TOLMAR NA
Dec, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-829) May 01, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: Treatment of pediatric patients with central precocious puberty

Dosage: POWDER

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

14. Ibrance patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47739

(Pediatric)

PFIZER NA
Sep, 2027

(1 year, 10 months from now)

US10723730

(Pediatric)

PFIZER NA
Aug, 2034

(8 years from now)

US11065250

(Pediatric)

PFIZER NA
Feb, 2037

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Chemical Entity Exclusivity(NCE) Feb 03, 2020
M(M-14) Sep 16, 2028
Pediatric Exclusivity(PED) Mar 16, 2029

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 16 March, 2028

Market Authorisation Date: 03 February, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

15. Inlexzo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403086 JANSSEN BIOTECH NA
Jun, 2030

(4 years from now)

US8679094 JANSSEN BIOTECH NA
Apr, 2032

(6 years from now)

US10729823 JANSSEN BIOTECH NA
Aug, 2034

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 09, 2028

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 September, 2025

Treatment: NA

Dosage: SYSTEM

More Information on Dosage

INLEXZO family patents

Family Patents

16. Kabiven In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12390398 FRESENIUS KABI USA NA
May, 2036

(10 years from now)




More Information on Dosage

KABIVEN IN PLASTIC CONTAINER family patents

Family Patents

17. Kisqali patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12419894 NOVARTIS NA
Apr, 2036

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-783) Jul 18, 2021
New Indication(I-784) Jul 18, 2021
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024
New Indication(I-950) Sep 17, 2027

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: NA

Dosage: TABLET

How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage

KISQALI family patents

Family Patents

18. Kisqali Femara Co-pack (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12419894 NOVARTIS NA
Apr, 2036

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Patient Population(NPP) Dec 10, 2024
New Indication(I-951) Sep 17, 2027

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: NA

Dosage: TABLET

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

Family Patents

19. Kloxxado patent expiration

Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12414915 HIKMA NA
Aug, 2034

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2024

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 August, 2025

Treatment: NA

Dosage: SPRAY

How can I launch a generic of KLOXXADO before it's drug patent expiration?
More Information on Dosage

KLOXXADO family patents

Family Patents

20. Koselugo patent expiration

KOSELUGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2026

(4 months from now)

US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2026

(4 months from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(1 year, 1 month from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(1 year, 1 month from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

Market Authorisation Date: 10 September, 2025

Treatment: Treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: GRANULE

More Information on Dosage

KOSELUGO family patents

Family Patents

21. Kyxata patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12427104 AVYXA HOLDINGS NA
Apr, 2045

(19 years from now)




Drugs and Companies using CARBOPLATIN ingredient

Market Authorisation Date: 08 August, 2025

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

KYXATA family patents

Family Patents

22. Kyzatrex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403146 MARIUS NA
Mar, 2041

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 27, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE

More Information on Dosage

KYZATREX family patents

Family Patents

23. Lutathera patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12415003 AAA USA INC NA
Jul, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 26, 2023
Orphan Drug Exclusivity(ODE-166) Jan 26, 2025
New Patient Population(NPP) Apr 23, 2027
Orphan Drug Exclusivity(ODE-479) Apr 23, 2031
Pediatric Exclusivity(PED) Oct 23, 2031

Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient

NCE-1 date: 23 October, 2030

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (gep-nets), including foregut, midgut, and hindgut neuroen...

Dosage: SOLUTION

More Information on Dosage

LUTATHERA family patents

Family Patents

24. Lytgobi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(7 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
ODE*(ODE*) Sep 30, 2029
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET

More Information on Dosage

LYTGOBI family patents

Family Patents

25. Micafungin In Sodium Chloride 0.9% patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403173 BAXTER HLTHCARE CORP NA
Dec, 2037

(12 years from now)




Drugs and Companies using MICAFUNGIN SODIUM ingredient

Market Authorisation Date: 29 September, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

MICAFUNGIN IN SODIUM CHLORIDE 0.9% family patents

Family Patents

26. Ohtuvayre patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12409180 VERONA PHARMA NA
Feb, 2043

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 26, 2029

Drugs and Companies using ENSIFENTRINE ingredient

NCE-1 date: 26 June, 2028

Market Authorisation Date: 26 June, 2024

Treatment: NA

Dosage: SUSPENSION

More Information on Dosage

OHTUVAYRE family patents

Family Patents

27. Orladeyo patent expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10329260

(Pediatric)

BIOCRYST NA
Sep, 2035

(9 years from now)

US10689346

(Pediatric)

BIOCRYST NA
Sep, 2035

(9 years from now)

US11230530

(Pediatric)

BIOCRYST NA
Sep, 2035

(9 years from now)

US11708333

(Pediatric)

BIOCRYST NA
Sep, 2035

(9 years from now)

US12116346

(Pediatric)

BIOCRYST NA
Sep, 2035

(9 years from now)

US10125102

(Pediatric)

BIOCRYST NA
Oct, 2035

(9 years from now)

US10662160

(Pediatric)

BIOCRYST NA
May, 2040

(14 years from now)

US11117867

(Pediatric)

BIOCRYST NA
May, 2040

(14 years from now)

US11618733

(Pediatric)

BIOCRYST NA
May, 2040

(14 years from now)

US12344585

(Pediatric)

BIOCRYST NA
May, 2040

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 03, 2025
Orphan Drug Exclusivity(ODE-333) Dec 03, 2027
Pediatric Exclusivity(PED) Jun 03, 2028

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 04 June, 2027

Market Authorisation Date: 03 December, 2020

Treatment: NA

Dosage: CAPSULE

More Information on Dosage

ORLADEYO family patents

Family Patents

28. Otezla Xr patent expiration

OTEZLA XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
May, 2034

(8 years from now)

US11752129 AMGEN INC NA
May, 2042

(16 years from now)

US11969409 AMGEN INC NA
May, 2042

(16 years from now)




Drugs and Companies using APREMILAST ingredient

Market Authorisation Date: 29 August, 2025

Treatment: Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of plaque psoriasis by administering apremilast with food

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

OTEZLA XR family patents

Family Patents

29. Perikabiven In Plastic Container patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12390398 FRESENIUS KABI USA NA
May, 2036

(10 years from now)




More Information on Dosage

PERIKABIVEN IN PLASTIC CONTAINER family patents

Family Patents

30. Qbrelis patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12433931 AZURITY NA
Nov, 2035

(10 years from now)




Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of hypertension

Dosage: SOLUTION

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents

31. Rinvoq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12365689 ABBVIE NA
Oct, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 16, 2024
New Indication(I-880) Dec 14, 2024
New Indication(I-883) Jan 14, 2025
New Indication(I-886) Mar 16, 2025
New Indication(I-888) Apr 29, 2025
New Indication(I-919) May 18, 2026
New Indication(I-946) Apr 26, 2027
New Patient Population(NPP) Apr 26, 2027
New Indication(I-966) Apr 28, 2028
Orphan Drug Exclusivity(ODE-481) Apr 26, 2031

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

RINVOQ family patents

Family Patents

32. Sofdra patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12398102 BOTANIX SB NA
May, 2034

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 20, 2029

Drugs and Companies using SOFPIRONIUM BROMIDE ingredient

NCE-1 date: 20 June, 2028

Market Authorisation Date: 18 June, 2024

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: GEL, METERED

More Information on Dosage

SOFDRA family patents

Family Patents

33. Sotalol Hydrochloride patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12403109 ALTATHERA PHARMS LLC NA
Aug, 2028

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 02, 2016

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.

Dosage: SOLUTION

More Information on Dosage

SOTALOL HYDROCHLORIDE family patents

Family Patents

34. Subvenite patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11596634 OWP PHARMS NA
May, 2040

(14 years from now)

US11612566 OWP PHARMS NA
May, 2040

(14 years from now)




Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 16 September, 2025

Treatment: Conversion to monotherapy for partial-onset seizures in patients 16 years and older

Dosage: SUSPENSION

More Information on Dosage

SUBVENITE family patents

Family Patents

35. Tezruly patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12427108 NOVITIUM PHARMA NA
Feb, 2041

(15 years from now)




Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 July, 2024

Treatment: Treatment of symptomatic benign prostatic hyperplasia (bph) in patients who are in need of a liquid composition of terazosin

Dosage: SOLUTION

More Information on Dosage

TEZRULY family patents

Family Patents

36. Tonmya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117936 TONIX NA
Mar, 2034

(8 years from now)

US10864175 TONIX NA
Mar, 2034

(8 years from now)

US9636408 TONIX NA
Mar, 2034

(8 years from now)

US9956188 TONIX NA
Mar, 2034

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 15, 2028

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 August, 2025

Treatment: NA

Dosage: TABLET

More Information on Dosage

TONMYA family patents

Family Patents

37. Trelegy Ellipta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12396986 GLAXOSMITHKLINE NA
Nov, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
New Indication(I-775) Apr 24, 2021
New Indication(I-843) Sep 09, 2023
New Strength(NS) Sep 09, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: POWDER

More Information on Dosage

TRELEGY ELLIPTA family patents

Family Patents

38. Vizz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12414942 LENZ THERAP NA
Mar, 2044

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2030

Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2029

Market Authorisation Date: 31 July, 2025

Treatment: Treatment of presbyopia

Dosage: SOLUTION/DROPS

More Information on Dosage

VIZZ family patents

Family Patents

39. Vykat Xr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12419895 SOLENO THERAP NA
Nov, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 26, 2028

Drugs and Companies using DIAZOXIDE CHOLINE ingredient

Market Authorisation Date: 26 March, 2025

Treatment: Treating hyperphagia and reducing food-related behaviors in prader-willi syndrome patients

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

VYKAT XR family patents

Family Patents

40. Wayrilz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9580427 GENZYME CORP NA
Mar, 2033

(7 years from now)

US8940744 GENZYME CORP NA
Sep, 2033

(7 years from now)

US9266895 GENZYME CORP NA
Sep, 2033

(7 years from now)

US9994576 GENZYME CORP NA
Sep, 2033

(7 years from now)

US11708370 GENZYME CORP NA
Feb, 2041

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12178818 GENZYME CORP NA
Oct, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 29, 2030

Drugs and Companies using RILZABRUTINIB ingredient

NCE-1 date: 29 August, 2029

Market Authorisation Date: 29 August, 2025

Treatment: Method for treating adult patients with persistent or chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment, by achieving a platelet count of at least 50,...

Dosage: TABLET

More Information on Dosage

WAYRILZ family patents

Family Patents

41. Xatmep patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12396947 AZURITY NA
Jan, 2033

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Apr 25, 2024
Orphan Drug Exclusivity(ODE-137) Apr 25, 2024
Orphan Drug Exclusivity(ODE-138) Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

XATMEP family patents

Family Patents

42. Xromi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12409156 NOVA LABS LTD NA
Dec, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 04, 2027
Orphan Drug Exclusivity(ODE-470) Apr 04, 2031

Drugs and Companies using HYDROXYUREA ingredient

Market Authorisation Date: 04 April, 2024

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

XROMI family patents

Family Patents

43. Zoryve patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12390453 ARCUTIS NA
Jun, 2037

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 15, 2026
New Patient Population(NPP) Oct 05, 2026
New Strength(NS) Jul 09, 2027
New Indication(I-969) May 22, 2028

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 15 December, 2023

Treatment: NA

Dosage: FOAM

More Information on Dosage

ZORYVE family patents

Family Patents